Interestingly, essentially identical effects were observed upon intratumoral administration of an inhibitor of NLRP3 inflammasomes (MCC950) or an IL-1 receptor antagonist (IL1-Ra), indicating the critical role of inflammasomes activation and IL-1β signaling in tumor growth in an MCF-7 xenograft model. The gene discussed is NLRP3; the disease is neoplasm.